We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
Read MoreHide Full Article
Intuitive Surgical Inc (ISRG - Free Report) is scheduled to release fourth-quarter 2018 results on Jan 24, after market close. The company expects steady growth in the Instruments and Accessories segment.
Revenues from other segments are likely to bolster the company’s performance in the to-be-reported quarter.
Third-Quarter Results
Intuitive Surgical reported adjusted earnings of $2.83 per share in the third quarter of 2018, which surpassed the Zacks Consensus Estimate of $2.65. Adjusted earnings improved 1.8% year over year. Revenues amounted to $920.9 million, up 14% from the prior-year quarter number. The figure also surpassed the Zacks Consensus Estimate of $918.6 million.
In the trailing four quarters, the company exceeded the consensus mark, the average being 13.2%.
Which Way Are Estimates Treading?
For the fourth quarter, the Zacks Consensus Estimate for revenues is pinned at $917 million, indicating a year-over-year increase of 13.8%. The same for earnings is pegged at $2.65, reflecting a 4.3% decline year over year.
Let’s delve deeper.
Instruments & Accessories – A Key Catalyst
The Instruments and Accessories segment is expected to deliver solid performance in the fourth quarter. Not to forget, the segment performed impressively in the last reported quarter as well, contributing 52.8% to total revenues. Markedly, the flagship da Vinci surgical system continues to be a revenue driver for the segment. In the third quarter, da Vinci procedures grew approximately 21.2% fromyear-ago quarter’s figure.
The Zacks Consensus Estimate for Instruments & Accessories’fourth-quarter revenues in the United States is pegged at $407 million, mirroring a 10.6% rise on a sequential basis.
Other Factors at Play
Preliminary Results
Intuitive Surgicalrecently announced preliminary results for fourth-quarter 2018. Revenues are anticipated to total $1.05 billion, up 17% year over year. Preliminary instrument and accessory revenues increased approximately 18% to approximately $539 million, up 17.9% year over year driven primarily by growth of the da Vinci procedure. Moreover, the company contributed $25 million for establishing the Intuitive Foundation to help reduce the global burden of disease and suffering through research, education and philanthropy.
Fourth-quarter worldwide da Vinci procedures increased approximately 19% from the year-ago quarter. Notably, the company shipped 290 da Vinci Surgical Systems in the quarter compared with 216 in the year-ago period. In 2019, Intuitive Surgical expects da Vinci procedures to grow approximately 13-17%.
It is also encouraging to note that the China National Health Commission recently announced a new quota to allow the sale of 154 new surgical robots into China through 2020, which includes da Vinci Surgical Systems. Additionally, Intuitive Surgical obtained clearance for the da Vinci Xi Surgical System in China in late 2018.
In Taiwan, Intuitive Surgical began direct operations for da Vinci products and services in late 2018.
The Services Segment
Intuitive Surgical’s fourth-quarter results are expected to witness strong contribution from the Services segment as well.
The Zacks Consensus Estimate for net revenues at this segment is pegged at $168 million, up 5% year over year. In the last reported quarter, Services revenues came in at $160 million, up 2.7% from the year-ago quarter’s tally.
For Services revenues in the United States, the consensus mark is pinned at $120 million, reflecting an increase of 7.1% on a sequential basis.
What Does Our Model Say?
Per our proven model, a stock needs to have both — a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for an earnings beat. This is exactly the case here as you will see below.You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Intuitive Surgical has an Earnings ESP of +1.34%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intuitive Surgical carries a Zacks Rank #2.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
PerkinElmer has an Earnings ESP of +0.77% and a Zacks Rank #3.
Baxter International (BAX - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #3.
DexCom (DXCM - Free Report) has an Earnings ESP of +23.03% and a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
Intuitive Surgical Inc (ISRG - Free Report) is scheduled to release fourth-quarter 2018 results on Jan 24, after market close. The company expects steady growth in the Instruments and Accessories segment.
Revenues from other segments are likely to bolster the company’s performance in the to-be-reported quarter.
Third-Quarter Results
Intuitive Surgical reported adjusted earnings of $2.83 per share in the third quarter of 2018, which surpassed the Zacks Consensus Estimate of $2.65. Adjusted earnings improved 1.8% year over year. Revenues amounted to $920.9 million, up 14% from the prior-year quarter number. The figure also surpassed the Zacks Consensus Estimate of $918.6 million.
In the trailing four quarters, the company exceeded the consensus mark, the average being 13.2%.
Which Way Are Estimates Treading?
For the fourth quarter, the Zacks Consensus Estimate for revenues is pinned at $917 million, indicating a year-over-year increase of 13.8%. The same for earnings is pegged at $2.65, reflecting a 4.3% decline year over year.
Let’s delve deeper.
Instruments & Accessories – A Key Catalyst
The Instruments and Accessories segment is expected to deliver solid performance in the fourth quarter. Not to forget, the segment performed impressively in the last reported quarter as well, contributing 52.8% to total revenues. Markedly, the flagship da Vinci surgical system continues to be a revenue driver for the segment. In the third quarter, da Vinci procedures grew approximately 21.2% fromyear-ago quarter’s figure.
The Zacks Consensus Estimate for Instruments & Accessories’fourth-quarter revenues in the United States is pegged at $407 million, mirroring a 10.6% rise on a sequential basis.
Other Factors at Play
Preliminary Results
Intuitive Surgicalrecently announced preliminary results for fourth-quarter 2018. Revenues are anticipated to total $1.05 billion, up 17% year over year. Preliminary instrument and accessory revenues increased approximately 18% to approximately $539 million, up 17.9% year over year driven primarily by growth of the da Vinci procedure. Moreover, the company contributed $25 million for establishing the Intuitive Foundation to help reduce the global burden of disease and suffering through research, education and philanthropy.
Fourth-quarter worldwide da Vinci procedures increased approximately 19% from the year-ago quarter. Notably, the company shipped 290 da Vinci Surgical Systems in the quarter compared with 216 in the year-ago period. In 2019, Intuitive Surgical expects da Vinci procedures to grow approximately 13-17%.
It is also encouraging to note that the China National Health Commission recently announced a new quota to allow the sale of 154 new surgical robots into China through 2020, which includes da Vinci Surgical Systems. Additionally, Intuitive Surgical obtained clearance for the da Vinci Xi Surgical System in China in late 2018.
In Taiwan, Intuitive Surgical began direct operations for da Vinci products and services in late 2018.
The Services Segment
Intuitive Surgical’s fourth-quarter results are expected to witness strong contribution from the Services segment as well.
The Zacks Consensus Estimate for net revenues at this segment is pegged at $168 million, up 5% year over year. In the last reported quarter, Services revenues came in at $160 million, up 2.7% from the year-ago quarter’s tally.
For Services revenues in the United States, the consensus mark is pinned at $120 million, reflecting an increase of 7.1% on a sequential basis.
What Does Our Model Say?
Per our proven model, a stock needs to have both — a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for an earnings beat. This is exactly the case here as you will see below.You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings ESP: Intuitive Surgical has an Earnings ESP of +1.34%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Intuitive Surgical carries a Zacks Rank #2.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Intuitive Surgical, Inc. Price and EPS Surprise
Intuitive Surgical, Inc. Price and EPS Surprise | Intuitive Surgical, Inc. Quote
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
PerkinElmer has an Earnings ESP of +0.77% and a Zacks Rank #3.
Baxter International (BAX - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #3.
DexCom (DXCM - Free Report) has an Earnings ESP of +23.03% and a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>